Drug details:
Molecular formula: C₂₁H₂₀O₁₁

Standard name: 3,5,8-trihydroxy-2-(4-hydroxyphenyl)-7-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one

Synonyms:

Herbacetin 7-rhamnoside Herbacetin 7-o-alpha-L-rhamnopyranoside Herbacetin 7-O-rhamnopyranoside 4H-1-Benzopyran-4-one, 7-((6-deoxy-alpha-L-mannopyranosyl)oxy)-3,5,8-trihydroxy-2-(4-hydroxyphenyl)- RhodioninHerbacetin 7-O-alpha-rhamnopyranoside HERBACETIN 7-O-.ALPHA.-L-RHAMNOPYRANOSIDE 4H-1-BENZOPYRAN-4-ONE, 7-((6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)OXY)-3,5,8-TRIHYDROXY-2-(4-HYDROXYPHENYL)-

Curated SMILES: C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(C3=C(C(=C2)O)C(=O)C(=C(O3)C4=CC=C(C=C4)O)O)O)O)O)O

Evidence for compound's anti-virulence activity:

Staphylococcus
Related VFcategory: Others; Adherence; Biofilm
Target: SrtA
Drug effect: Inhibits SrtA activity and SrtA-related virulence phenotypes including fibrinogen adhesion, biofilm formation and surface protein (SpA) anchoring.
Max phase: Preclinical (in vivo)
Publication:
Wang X, et al., 2022. The protection effect of rhodionin against methicillin-resistant Staphylococcus aureus-induced pneumonia through sortase A inhibition. World J Microbiol Biotechnol 39(1):18.